IM-250 is a potent HSV-1 helicase primase inhibitor, inhibits HSV-1 replication with IC50 of 20 nM (clinical isolate of HSV-1).
IM-250 dispalys similar IC50 values (20-30 nM) against ACV-resistant HSV-1 clinical isolates 2 and 3 and ACV-resistant HSV-2 clinical isolates 7 and 8.
IM-250 exhibits a broad therapeutic window against HSV-1 in vitro with pronounced higher SI values as obtained for acyclovir (ACV).
IM-250 shows in vivo efficacy and attenuates viral burden in HSV-1 infection mouse model.
